Home
Latest
E-paper
Companies
Industry
Economy
Blueprint
Finance
Markets
Budget
India News
Politics
External Affairs Defence Security
World News
Opinion
Technology
Immigration
Specials
Partner Content
Sports
Cricket
Lifestyle
Entertainment
Social Viral
Health
BS Decoded
Books
Education
Newsletters
Web Stories
BS at 50
Multimedia
Sudoku
Crossword
BS Apps
Management
Premium
Indulgence
Explore Business Standard
BFSI Insight Summit
Events
About Us
BS Support
Popular Search
Roche eyes quick FDA approval of risdiplam for spinal muscular atrophy
The US Food and Drug Administration granted priority review for risdiplam, an oral medicine for those with the potentially deadly muscle-wasting disorder
Novartis' skin cancer drug posts win in trials, Roche flops
Novartis's mix of Tafinlar and Mekinist slashed the risk of melanoma returning or death by 53%
